Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

Abstract

BackgroundWe present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers.MethodsThe study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST). Patients were categorized as 20 “controlled disease” (stable disease, partial response, or complete response) or 37 progressive disease). We used 3D-slicer to segment target lesions on standard-of-care, pretreatment contrast enhanced CT scans. We extracted 610 features (10 histogram-based features and 600 second-order texture features) from each volume of interest. Least absolute shrinkage and selection operator logistic regression was used to detect the most discriminatory features. Selected features were used to create a classification model, using XGBoost, for the prediction of tumor response to pembrolizumab. Leave-one-out cross-validation was performed to assess model performance.FindingsThe 10 most relevant radiomics features were selected; XGBoost-based classification successfully differentiated between controlled disease (complete response, partial response, stable disease) and progressive disease with high accuracy, sensitivity, and specificity in patients assessed by RECIST (94.7%, 97.3%, and 90%, respectively; p<0.001) and in patients assessed by irRECIST (94.7%, 93.9%, and 95.8%, respectively; p<0.001). Additionally, the common features of the RECIST and irRECIST groups also highly predicted pembrolizumab response with accuracy, sensitivity, specificity, and p value of 94.7%, 97%, 90%, p<0.001% and 96%, 96%, 95%, p<0.001, respectively.ConclusionOur radiomics-based signature identified imaging differences that predicted pembrolizumab response in patients with advanced rare cancer.InterpretationOur radiomics-based signature identified imaging differences that predicted pembrolizumab response in patients with advanced rare cancer.

Multi-Organ Omics-Based Prediction for Adaptive Radiation Therapy Eligibility in Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy

“…First, the outstanding predictability of Radiomics in this study may largely lie in its unique capability in unraveling intrinsic tissue property regarding response to treatment perturbations, which can be tissue-type dependent and patient-specific. There is mounting evidence in the literature showing the power of Radiomics in predicting treatment response in various cancer diseases (24)(25)(26)(27)(28)(29). For instance, Hou et al investigated CECT-based biomarkers for prediction of therapeutic response to chemo-radiotherapy in esophageal carcinoma and reported the discriminability of their model in AUC ranging from 0.686 to 0.727 (24).…”

“…Until more recently, emerging Radiomics has opened up opportunities for divulging concealed biologic traits and genetic association of tumor and organ structures (21)(22)(23). There is mounting evidence in the literature showing the power of Radiomics in predicting treatment response on the ground of volume shrinkage in various cancer diseases (24)(25)(26)(27)(28)(29), which has laid great foundation for Radiomics prediction of ART demand in cancer patients. Ramella et al performed radiomic analysis on pre-treatment CT images of replanned non-small cell lung cancer patients and generated a radiomic signature for prediction of tumor shrinkage during chemo-radiotherapy, yielding an Area Under the Receiver Characteristics Curves (AUC) of 0.82 (27).…”

A review in radiomics: Making personalized medicine a reality via routine imaging

“…Delta-radiomics promises to improve diagnosis, prognosis, prediction, monitoring, image-based intervention, or assessment of therapeutic response. 124,125 Delta radiomics has been proven effective in the study of immunotherapy response 126,127 or to predict recurrence in oncological patients. 128…”

Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology

“…1 Radiomics is a high-throughput computational process that unlocks microscale quantitative data hidden within conventional imaging, not otherwise visualized by the naked human eye; radiogenomics is the linkage between imaging and genomics data. 2,3 With use of radiomics analysis, a patient's scans are converted into mineable quantitative data to which machine learning (ML) techniques can be applied for integrative analysis. This process has enabled the identification of quantitative imaging markers and signature models that are reflective of microscopic tumor biology, which has led to enhanced, biologically relevant classification, tumor grading, survival prediction, and treatment response in adult and pediatric brain tumors.…”